Evaluating the potential impact of using the novel urine chip in lung cancer

This study focuses on the comparison between the current cost, utility and life-years for lung cancer in the healthcare system of the Netherlands without screening and the cost, utility and life-years for lung cancer in the healthcare system of the Netherlands after using lung cancer screening for a highrisk group identified with the novel urine chip.